Literature DB >> 26380543

Toward Personalized Medicine: Does Genetic Diagnosis of Pediatric Cardiomyopathy Influence Patient Management?

Teresa M Lee1, Stephanie M Ware2.   

Abstract

A goal of personalized medicine is to provide increasingly sophisticated, individualized approaches to management and therapy for disease. Genetics is the engine that drives personalized medicine, holding the promise of therapeutics directed toward the unique needs of each patient. The 3rd International Conference on Cardiomyopathy in Children provided a forum to discuss the current status of personalized approaches to diagnosis, management, and therapy in the pediatric cardiomyopathy population. This review will focus on the importance of genetic diagnosis in this population as a necessary first step toward understanding the best approach to management and influencing disease outcome. The genetic heterogeneity of cardiomyopathy in children, the implications of specific genotypes, the ability to risk stratify based on genotype, and the impact on cascade screening in family members will be discussed.

Entities:  

Keywords:  cascade screening; metabolic; sarcomere; syndrome

Year:  2015        PMID: 26380543      PMCID: PMC4568845          DOI: 10.1016/j.ppedcard.2015.01.008

Source DB:  PubMed          Journal:  Prog Pediatr Cardiol        ISSN: 1058-9813


  34 in total

1.  Design and implementation of the North American Pediatric Cardiomyopathy Registry.

Authors:  M A Grenier; S K Osganian; G F Cox; J A Towbin; S D Colan; P R Lurie; L A Sleeper; E J Orav; S E Lipshultz
Journal:  Am Heart J       Date:  2000-02       Impact factor: 4.749

2.  Clinical features and outcomes of childhood dilated cardiomyopathy: results from a national population-based study.

Authors:  Piers E F Daubeney; Alan W Nugent; Patty Chondros; John B Carlin; Steven D Colan; Michael Cheung; Andrew M Davis; C W Chow; Robert G Weintraub
Journal:  Circulation       Date:  2006-11-20       Impact factor: 29.690

3.  Incidence, causes, and outcomes of dilated cardiomyopathy in children.

Authors:  Jeffrey A Towbin; April M Lowe; Steven D Colan; Lynn A Sleeper; E John Orav; Sarah Clunie; Jane Messere; Gerald F Cox; Paul R Lurie; Daphne Hsu; Charles Canter; James D Wilkinson; Steven E Lipshultz
Journal:  JAMA       Date:  2006-10-18       Impact factor: 56.272

4.  Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention.

Authors:  Barry J Maron; Jeffrey A Towbin; Gaetano Thiene; Charles Antzelevitch; Domenico Corrado; Donna Arnett; Arthur J Moss; Christine E Seidman; James B Young
Journal:  Circulation       Date:  2006-03-27       Impact factor: 29.690

5.  Furthering the link between the sarcomere and primary cardiomyopathies: restrictive cardiomyopathy associated with multiple mutations in genes previously associated with hypertrophic or dilated cardiomyopathy.

Authors:  Colleen Caleshu; Rahul Sakhuja; Robert L Nussbaum; Nelson B Schiller; Philip C Ursell; Celeste Eng; Teresa De Marco; Dana McGlothlin; Esteban González Burchard; J Eduardo Rame
Journal:  Am J Med Genet A       Date:  2011-08-05       Impact factor: 2.802

6.  Pediatric cardiomyopathy: importance of genetic and metabolic evaluation.

Authors:  Steven J Kindel; Erin M Miller; Resmi Gupta; Linda H Cripe; Robert B Hinton; Robert L Spicer; Jeffrey A Towbin; Stephanie M Ware
Journal:  J Card Fail       Date:  2012-03-10       Impact factor: 5.712

7.  MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation.

Authors:  Xue Wu; Jeremy Simpson; Jenny H Hong; Kyoung-Han Kim; Nirusha K Thavarajah; Peter H Backx; Benjamin G Neel; Toshiyuki Araki
Journal:  J Clin Invest       Date:  2011-02-21       Impact factor: 14.808

8.  Uptake of genetic counselling and predictive DNA testing in hypertrophic cardiomyopathy.

Authors:  Imke Christiaans; Erwin Birnie; Gouke J Bonsel; Arthur Am Wilde; Irene M van Langen
Journal:  Eur J Hum Genet       Date:  2008-05-14       Impact factor: 4.246

9.  Shared genetic causes of cardiac hypertrophy in children and adults.

Authors:  Hiroyuki Morita; Heidi L Rehm; Andres Menesses; Barbara McDonough; Amy E Roberts; Raju Kucherlapati; Jeffrey A Towbin; J G Seidman; Christine E Seidman
Journal:  N Engl J Med       Date:  2008-04-09       Impact factor: 91.245

10.  Genetic evaluation of cardiomyopathy--a Heart Failure Society of America practice guideline.

Authors:  Ray E Hershberger; Joann Lindenfeld; Luisa Mestroni; Christine E Seidman; Matthew R G Taylor; Jeffrey A Towbin
Journal:  J Card Fail       Date:  2009-03       Impact factor: 5.712

View more
  1 in total

Review 1.  Precision and Personalized Medicine: How Genomic Approach Improves the Management of Cardiovascular and Neurodegenerative Disease.

Authors:  Oriana Strianese; Francesca Rizzo; Michele Ciccarelli; Gennaro Galasso; Ylenia D'Agostino; Annamaria Salvati; Carmine Del Giudice; Paola Tesorio; Maria Rosaria Rusciano
Journal:  Genes (Basel)       Date:  2020-07-06       Impact factor: 4.096

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.